Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIF-1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Rectal, Vaginal, Buccal, Transdermal, Intratumoral, Parenteral, Implant
01
Overview
HIF-1 siRNA (Hypoxia-inducible factor 1 small interfering RNA) refers to a class of double-stranded RNA molecules designed to specifically target and silence the expression of Hypoxia-inducible factor 1-alpha (HIF-1α) mRNA. HIF-1α is a key transcription factor that regulates cellular responses to hypoxia, promoting angiogenesis, metabolic reprogramming, and cell survival under low-oxygen conditions. In oncology, HIF-1α is frequently upregulated and associated with tumor progression, metastasis, and resistance to chemotherapy and radiation. Silencing HIF-1α using siRNA has been widely investigated in preclinical research as a therapeutic strategy to inhibit tumor growth, overcome drug resistance, and suppress angiogenesis, often utilizing various nanoparticle delivery systems to facilitate cellular uptake.
- Other names
- HIF-1 alpha siRNAHIF1 alpha siRNAHIF 1 alpha siRNAHIF-1a siRNAHIF1a siRNAHIF 1a siRNAHIF-1α siRNAHypoxia-inducible factor 1-alpha siRNA
02
Targets
HIF1A (Hypoxia-inducible factor 1-alpha)
Beyond the preview
Go deeper on HIF-1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIF-1 siRNA.